According to Roche's latest financial reports the company has $12.50 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $12.50 B | 18.24% |
2022-12-31 | $10.57 B | -25.87% |
2021-12-31 | $14.26 B | 1.94% |
2020-12-31 | $13.99 B | 14.28% |
2019-12-31 | $12.24 B | -8.21% |
2018-12-31 | $13.33 B | 8.25% |
2017-12-31 | $12.32 B | 37.82% |
2016-12-31 | $8.93 B | -3.69% |
2015-12-31 | $9.28 B | -21.59% |
2014-12-31 | $11.83 B | -12% |
2013-12-31 | $13.45 B | -12.25% |
2012-12-31 | $15.33 B | 27.42% |
2011-12-31 | $12.03 B | 3.14% |
2010-12-31 | $11.66 B | -34.96% |
2009-12-31 | $17.93 B | -9.95% |
2008-12-31 | $19.91 B | -6.84% |
2007-12-31 | $21.37 B | 6.9% |
2006-12-31 | $19.99 B | 26% |
2005-12-31 | $15.87 B | 39.26% |
2004-12-31 | $11.39 B | -12.43% |
2003-12-31 | $13.01 B | -24.88% |
2002-12-31 | $17.32 B | -35.53% |
2001-12-31 | $26.87 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $22.92 B | 83.41% | ๐บ๐ธ USA |
Novartis NVS | $13.96 B | 11.69% | ๐จ๐ญ Switzerland |
Pfizer PFE | $12.69 B | 1.52% | ๐บ๐ธ USA |
Abbott Laboratories ABT | $7.27 B | -41.77% | ๐บ๐ธ USA |
Amgen AMGN | $10.94 B | -12.45% | ๐บ๐ธ USA |
Sanofi SNY | $9.92 B | -20.58% | ๐ซ๐ท France |
Becton Dickinson BDX | $1.18 B | -90.54% | ๐บ๐ธ USA |
Merck MRK | $7.09 B | -43.26% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $6.35 B | -49.16% | ๐ฌ๐ง UK |